#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Obesity and related disorders are widely perceived by both the public and the scientific community as a major and growing threat to global human health ; more than 2 billion people worldwide are currently overweight or obese , and obesity is associated with an increased hazard for a range of ailments , including type-2 diabetes , cardiovascular diseases and hypertension , multiple cancer types , chronic inflammatory diseases , dementia , and neurodegenerative diseases .
2-1	16-23	Obesity	abstract|abstract[3]	new|new[3]	coref|coref	2-40|13-12[100_3]
2-2	24-27	and	abstract[3]	new[3]	_	_
2-3	28-35	related	abstract[3]|abstract[4]	new[3]|new[4]	coref	13-14[101_4]
2-4	36-45	disorders	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-5	46-49	are	_	_	_	_
2-6	50-56	widely	_	_	_	_
2-7	57-66	perceived	_	_	_	_
2-8	67-69	by	_	_	_	_
2-9	70-74	both	person[5]	new[5]	_	_
2-10	75-78	the	person[5]	new[5]	_	_
2-11	79-85	public	person[5]	new[5]	_	_
2-12	86-89	and	_	_	_	_
2-13	90-93	the	organization[6]	new[6]	_	_
2-14	94-104	scientific	organization[6]	new[6]	_	_
2-15	105-114	community	organization[6]	new[6]	_	_
2-16	115-117	as	_	_	_	_
2-17	118-119	a	abstract[7]	new[7]	_	_
2-18	120-125	major	abstract[7]	new[7]	_	_
2-19	126-129	and	abstract[7]	new[7]	_	_
2-20	130-137	growing	abstract[7]	new[7]	_	_
2-21	138-144	threat	abstract[7]	new[7]	_	_
2-22	145-147	to	abstract[7]	new[7]	_	_
2-23	148-154	global	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-24	155-160	human	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-25	161-167	health	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-26	168-169	;	_	_	_	_
2-27	170-174	more	person[9]	new[9]	coref	9-12[64_9]
2-28	175-179	than	person[9]	new[9]	_	_
2-29	180-181	2	person[9]	new[9]	_	_
2-30	182-189	billion	person[9]	new[9]	_	_
2-31	190-196	people	person[9]	new[9]	_	_
2-32	197-206	worldwide	_	_	_	_
2-33	207-210	are	_	_	_	_
2-34	211-220	currently	_	_	_	_
2-35	221-231	overweight	_	_	_	_
2-36	232-234	or	_	_	_	_
2-37	235-240	obese	_	_	_	_
2-38	241-242	,	_	_	_	_
2-39	243-246	and	_	_	_	_
2-40	247-254	obesity	abstract	giv	coref	4-20
2-41	255-257	is	_	_	_	_
2-42	258-268	associated	_	_	_	_
2-43	269-273	with	_	_	_	_
2-44	274-276	an	abstract[11]	new[11]	_	_
2-45	277-286	increased	abstract[11]	new[11]	_	_
2-46	287-293	hazard	abstract[11]	new[11]	_	_
2-47	294-297	for	abstract[11]	new[11]	_	_
2-48	298-299	a	abstract[11]	new[11]	_	_
2-49	300-305	range	abstract[11]	new[11]	_	_
2-50	306-308	of	abstract[11]	new[11]	_	_
2-51	309-317	ailments	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-52	318-319	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-53	320-329	including	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-54	330-336	type-2	abstract[11]|abstract[12]|abstract[13]	new[11]|new[12]|new[13]	_	_
2-55	337-345	diabetes	abstract[11]|abstract[12]|abstract[13]	new[11]|new[12]|new[13]	_	_
2-56	346-347	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-57	348-362	cardiovascular	abstract[11]|abstract[12]|abstract[14]	new[11]|new[12]|new[14]	_	_
2-58	363-371	diseases	abstract[11]|abstract[12]|abstract[14]	new[11]|new[12]|new[14]	_	_
2-59	372-375	and	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-60	376-388	hypertension	abstract[11]|abstract[12]|abstract	new[11]|new[12]|new	_	_
2-61	389-390	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-62	391-399	multiple	abstract[11]|abstract[12]|abstract[17]	new[11]|new[12]|new[17]	_	_
2-63	400-406	cancer	abstract[11]|abstract[12]|abstract|abstract[17]	new[11]|new[12]|new|new[17]	_	_
2-64	407-412	types	abstract[11]|abstract[12]|abstract[17]	new[11]|new[12]|new[17]	_	_
2-65	413-414	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-66	415-422	chronic	abstract[11]|abstract[12]|abstract[18]	new[11]|new[12]|new[18]	_	_
2-67	423-435	inflammatory	abstract[11]|abstract[12]|abstract[18]	new[11]|new[12]|new[18]	_	_
2-68	436-444	diseases	abstract[11]|abstract[12]|abstract[18]	new[11]|new[12]|new[18]	_	_
2-69	445-446	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-70	447-455	dementia	abstract[11]|abstract[12]|abstract	new[11]|new[12]|new	_	_
2-71	456-457	,	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-72	458-461	and	abstract[11]|abstract[12]	new[11]|new[12]	_	_
2-73	462-479	neurodegenerative	abstract[11]|abstract[12]|abstract[20]	new[11]|new[12]|new[20]	_	_
2-74	480-488	diseases	abstract[11]|abstract[12]|abstract[20]	new[11]|new[12]|new[20]	_	_
2-75	489-490	.	_	_	_	_

#Text=All these complications lead to a shortened life expectancy and have a high economic impact on healthcare systems .
3-1	491-494	All	abstract[21]	new[21]	_	_
3-2	495-500	these	abstract[21]	new[21]	_	_
3-3	501-514	complications	abstract[21]	new[21]	_	_
3-4	515-519	lead	_	_	_	_
3-5	520-522	to	_	_	_	_
3-6	523-524	a	abstract[23]	new[23]	_	_
3-7	525-534	shortened	abstract[23]	new[23]	_	_
3-8	535-539	life	abstract|abstract[23]	new|new[23]	_	_
3-9	540-550	expectancy	abstract[23]	new[23]	_	_
3-10	551-554	and	_	_	_	_
3-11	555-559	have	_	_	_	_
3-12	560-561	a	abstract[24]	new[24]	_	_
3-13	562-566	high	abstract[24]	new[24]	_	_
3-14	567-575	economic	abstract[24]	new[24]	_	_
3-15	576-582	impact	abstract[24]	new[24]	_	_
3-16	583-585	on	abstract[24]	new[24]	_	_
3-17	586-596	healthcare	abstract[24]|organization|abstract[26]	new[24]|new|new[26]	_	_
3-18	597-604	systems	abstract[24]|abstract[26]	new[24]|new[26]	_	_
3-19	605-606	.	_	_	_	_

#Text=Lifestyle changes ( such as diet modification , physical activity , and behavioral interventions ) are the cornerstones of obesity treatment but maintaining a healthy lifestyle is often perceived as challenging .
4-1	607-616	Lifestyle	abstract|abstract[28]	new|new[28]	coref|coref	4-17[33_28]|4-24[36_0]
4-2	617-624	changes	abstract[28]	new[28]	_	_
4-3	625-626	(	abstract[28]	new[28]	_	_
4-4	627-631	such	abstract[28]	new[28]	_	_
4-5	632-634	as	abstract[28]	new[28]	_	_
4-6	635-639	diet	abstract[28]|event|abstract[30]	new[28]|new|new[30]	_	_
4-7	640-652	modification	abstract[28]|abstract[30]	new[28]|new[30]	_	_
4-8	653-654	,	abstract[28]	new[28]	_	_
4-9	655-663	physical	abstract[28]|abstract[31]	new[28]|new[31]	coref	20-25[177_31]
4-10	664-672	activity	abstract[28]|abstract[31]	new[28]|new[31]	_	_
4-11	673-674	,	abstract[28]	new[28]	_	_
4-12	675-678	and	abstract[28]	new[28]	_	_
4-13	679-689	behavioral	abstract[28]|event[32]	new[28]|new[32]	coref	5-8[39_32]
4-14	690-703	interventions	abstract[28]|event[32]	new[28]|new[32]	_	_
4-15	704-705	)	abstract[28]	new[28]	_	_
4-16	706-709	are	_	_	_	_
4-17	710-713	the	abstract[33]	giv[33]	coref	14-47[121_33]
4-18	714-726	cornerstones	abstract[33]	giv[33]	_	_
4-19	727-729	of	abstract[33]	giv[33]	_	_
4-20	730-737	obesity	abstract[33]|abstract|event[35]	giv[33]|giv|new[35]	coref|coref	6-4|24-20[206_35]
4-21	738-747	treatment	abstract[33]|event[35]	giv[33]|new[35]	_	_
4-22	748-751	but	_	_	_	_
4-23	752-763	maintaining	_	_	_	_
4-24	764-765	a	abstract[36]	giv[36]	_	_
4-25	766-773	healthy	abstract[36]	giv[36]	_	_
4-26	774-783	lifestyle	abstract[36]	giv[36]	_	_
4-27	784-786	is	_	_	_	_
4-28	787-792	often	_	_	_	_
4-29	793-802	perceived	_	_	_	_
4-30	803-805	as	_	_	_	_
4-31	806-817	challenging	_	_	_	_
4-32	818-819	.	_	_	_	_

#Text=Alternatively , pharmacotherapy and bariatric surgery represent more “ aggressive ” interventions , and are applicable only if the problem is severe .
5-1	820-833	Alternatively	_	_	_	_
5-2	834-835	,	_	_	_	_
5-3	836-851	pharmacotherapy	abstract	new	coref	6-1[41_0]
5-4	852-855	and	_	_	_	_
5-5	856-865	bariatric	event[38]	new[38]	_	_
5-6	866-873	surgery	event[38]	new[38]	_	_
5-7	874-883	represent	_	_	_	_
5-8	884-888	more	event[39]	giv[39]	_	_
5-9	889-890	“	event[39]	giv[39]	_	_
5-10	891-901	aggressive	event[39]	giv[39]	_	_
5-11	902-903	”	event[39]	giv[39]	_	_
5-12	904-917	interventions	event[39]	giv[39]	_	_
5-13	918-919	,	_	_	_	_
5-14	920-923	and	_	_	_	_
5-15	924-927	are	_	_	_	_
5-16	928-938	applicable	_	_	_	_
5-17	939-943	only	_	_	_	_
5-18	944-946	if	_	_	_	_
5-19	947-950	the	abstract[40]	new[40]	_	_
5-20	951-958	problem	abstract[40]	new[40]	_	_
5-21	959-961	is	_	_	_	_
5-22	962-968	severe	_	_	_	_
5-23	969-970	.	_	_	_	_

#Text=Current pharmacotherapy for obesity relies on a few drugs that are approved only for patients with BMI > 30 .
6-1	971-978	Current	abstract[41]	giv[41]	_	_
6-2	979-994	pharmacotherapy	abstract[41]	giv[41]	_	_
6-3	995-998	for	abstract[41]	giv[41]	_	_
6-4	999-1006	obesity	abstract[41]|abstract	giv[41]|giv	coref	13-12
6-5	1007-1013	relies	_	_	_	_
6-6	1014-1016	on	_	_	_	_
6-7	1017-1018	a	substance[43]	new[43]	coref	7-17[50_43]
6-8	1019-1022	few	substance[43]	new[43]	_	_
6-9	1023-1028	drugs	substance[43]	new[43]	_	_
6-10	1029-1033	that	substance[43]	new[43]	_	_
6-11	1034-1037	are	substance[43]	new[43]	_	_
6-12	1038-1046	approved	substance[43]	new[43]	_	_
6-13	1047-1051	only	substance[43]	new[43]	_	_
6-14	1052-1055	for	substance[43]	new[43]	_	_
6-15	1056-1064	patients	substance[43]|person[44]	new[43]|new[44]	_	_
6-16	1065-1069	with	substance[43]|person[44]	new[43]|new[44]	_	_
6-17	1070-1073	BMI	substance[43]|person[44]|abstract[45]	new[43]|new[44]|new[45]	_	_
6-18	1074-1075	>	substance[43]|person[44]|abstract[45]	new[43]|new[44]|new[45]	_	_
6-19	1076-1078	30	substance[43]|person[44]|abstract[45]	new[43]|new[44]|new[45]	_	_
6-20	1079-1080	.	_	_	_	_

#Text=With the only exception of orlistat ( which decreases fat absorption by inhibiting lipases ) , most of these drugs act through the central nervous system to reduce food intake ( via reduction of appetite or enhancement of satiety ) .
7-1	1081-1085	With	_	_	_	_
7-2	1086-1089	the	abstract[46]	new[46]	_	_
7-3	1090-1094	only	abstract[46]	new[46]	_	_
7-4	1095-1104	exception	abstract[46]	new[46]	_	_
7-5	1105-1107	of	abstract[46]	new[46]	_	_
7-6	1108-1116	orlistat	abstract[46]|substance[47]	new[46]|new[47]	_	_
7-7	1117-1118	(	abstract[46]|substance[47]	new[46]|new[47]	_	_
7-8	1119-1124	which	abstract[46]|substance[47]	new[46]|new[47]	_	_
7-9	1125-1134	decreases	abstract[46]|substance[47]	new[46]|new[47]	_	_
7-10	1135-1138	fat	abstract[46]|substance[47]|event[48]	new[46]|new[47]|new[48]	_	_
7-11	1139-1149	absorption	abstract[46]|substance[47]|event[48]	new[46]|new[47]|new[48]	_	_
7-12	1150-1152	by	_	_	_	_
7-13	1153-1163	inhibiting	_	_	_	_
7-14	1164-1171	lipases	substance	new	_	_
7-15	1172-1173	)	_	_	_	_
7-16	1174-1175	,	_	_	_	_
7-17	1176-1180	most	substance[50]	giv[50]	_	_
7-18	1181-1183	of	substance[50]	giv[50]	_	_
7-19	1184-1189	these	substance[50]	giv[50]	_	_
7-20	1190-1195	drugs	substance[50]	giv[50]	_	_
7-21	1196-1199	act	_	_	_	_
7-22	1200-1207	through	_	_	_	_
7-23	1208-1211	the	place[51]	new[51]	_	_
7-24	1212-1219	central	place[51]	new[51]	_	_
7-25	1220-1227	nervous	place[51]	new[51]	_	_
7-26	1228-1234	system	place[51]	new[51]	_	_
7-27	1235-1237	to	_	_	_	_
7-28	1238-1244	reduce	_	_	_	_
7-29	1245-1249	food	substance|abstract[53]	new|new[53]	_	_
7-30	1250-1256	intake	abstract[53]	new[53]	_	_
7-31	1257-1258	(	abstract[53]	new[53]	_	_
7-32	1259-1262	via	abstract[53]	new[53]	_	_
7-33	1263-1272	reduction	abstract[53]|event[54]	new[53]|new[54]	_	_
7-34	1273-1275	of	abstract[53]|event[54]	new[53]|new[54]	_	_
7-35	1276-1284	appetite	abstract[53]|event[54]|abstract	new[53]|new[54]|new	_	_
7-36	1285-1287	or	abstract[53]	new[53]	_	_
7-37	1288-1299	enhancement	abstract[53]|abstract[56]	new[53]|new[56]	_	_
7-38	1300-1302	of	abstract[53]|abstract[56]	new[53]|new[56]	_	_
7-39	1303-1310	satiety	abstract[53]|abstract[56]|abstract	new[53]|new[56]|new	_	_
7-40	1311-1312	)	abstract[53]	new[53]	_	_
7-41	1313-1314	.	_	_	_	_

#Text=However , the use of these treatments may lead to severe adverse effects and a long-term prescription is usually not recommended .
8-1	1315-1322	However	_	_	_	_
8-2	1323-1324	,	_	_	_	_
8-3	1325-1328	the	event[58]	new[58]	_	_
8-4	1329-1332	use	event[58]	new[58]	_	_
8-5	1333-1335	of	event[58]	new[58]	_	_
8-6	1336-1341	these	event[58]|abstract[59]	new[58]|new[59]	coref	9-25[69_59]
8-7	1342-1352	treatments	event[58]|abstract[59]	new[58]|new[59]	_	_
8-8	1353-1356	may	_	_	_	_
8-9	1357-1361	lead	_	_	_	_
8-10	1362-1364	to	_	_	_	_
8-11	1365-1371	severe	abstract[60]	new[60]	coref	9-30[70_60]
8-12	1372-1379	adverse	abstract[60]	new[60]	_	_
8-13	1380-1387	effects	abstract[60]	new[60]	_	_
8-14	1388-1391	and	_	_	_	_
8-15	1392-1393	a	abstract[61]	new[61]	_	_
8-16	1394-1403	long-term	abstract[61]	new[61]	_	_
8-17	1404-1416	prescription	abstract[61]	new[61]	_	_
8-18	1417-1419	is	_	_	_	_
8-19	1420-1427	usually	_	_	_	_
8-20	1428-1431	not	_	_	_	_
8-21	1432-1443	recommended	_	_	_	_
8-22	1444-1445	.	_	_	_	_

#Text=A nutraceutical approach could be a useful supporting tool to treat overweight people , since the use of natural compounds offers clear advantages over drug treatments in terms of adverse side effects , suitability for chronic treatments , marketability , and safety .
9-1	1446-1447	A	abstract[62]	new[62]	coref	9-6[63_62]
9-2	1448-1461	nutraceutical	abstract[62]	new[62]	_	_
9-3	1462-1470	approach	abstract[62]	new[62]	_	_
9-4	1471-1476	could	_	_	_	_
9-5	1477-1479	be	_	_	_	_
9-6	1480-1481	a	abstract[63]	giv[63]	_	_
9-7	1482-1488	useful	abstract[63]	giv[63]	_	_
9-8	1489-1499	supporting	abstract[63]	giv[63]	_	_
9-9	1500-1504	tool	abstract[63]	giv[63]	_	_
9-10	1505-1507	to	abstract[63]	giv[63]	_	_
9-11	1508-1513	treat	abstract[63]	giv[63]	_	_
9-12	1514-1524	overweight	abstract[63]|person[64]	giv[63]|giv[64]	_	_
9-13	1525-1531	people	abstract[63]|person[64]	giv[63]|giv[64]	_	_
9-14	1532-1533	,	_	_	_	_
9-15	1534-1539	since	_	_	_	_
9-16	1540-1543	the	abstract[65]	new[65]	_	_
9-17	1544-1547	use	abstract[65]	new[65]	_	_
9-18	1548-1550	of	abstract[65]	new[65]	_	_
9-19	1551-1558	natural	abstract[65]|substance[66]	new[65]|new[66]	_	_
9-20	1559-1568	compounds	abstract[65]|substance[66]	new[65]|new[66]	_	_
9-21	1569-1575	offers	_	_	_	_
9-22	1576-1581	clear	abstract[67]	new[67]	_	_
9-23	1582-1592	advantages	abstract[67]	new[67]	_	_
9-24	1593-1597	over	abstract[67]	new[67]	_	_
9-25	1598-1602	drug	abstract[67]|substance|abstract[69]	new[67]|new|giv[69]	coref	9-36[73_69]
9-26	1603-1613	treatments	abstract[67]|abstract[69]	new[67]|giv[69]	_	_
9-27	1614-1616	in	_	_	_	_
9-28	1617-1622	terms	_	_	_	_
9-29	1623-1625	of	_	_	_	_
9-30	1626-1633	adverse	abstract[70]|abstract[71]	giv[70]|giv[71]	coref|coref	9-30[71_70]|13-8[98_71]
9-31	1634-1638	side	abstract[70]|abstract[71]	giv[70]|giv[71]	_	_
9-32	1639-1646	effects	abstract[70]|abstract[71]	giv[70]|giv[71]	_	_
9-33	1647-1648	,	abstract[71]	giv[71]	_	_
9-34	1649-1660	suitability	abstract[71]|abstract[72]	giv[71]|new[72]	_	_
9-35	1661-1664	for	abstract[71]|abstract[72]	giv[71]|new[72]	_	_
9-36	1665-1672	chronic	abstract[71]|abstract[72]|abstract[73]	giv[71]|new[72]|giv[73]	_	_
9-37	1673-1683	treatments	abstract[71]|abstract[72]|abstract[73]	giv[71]|new[72]|giv[73]	_	_
9-38	1684-1685	,	abstract[71]	giv[71]	_	_
9-39	1686-1699	marketability	abstract[71]|abstract	giv[71]|new	_	_
9-40	1700-1701	,	abstract[71]	giv[71]	_	_
9-41	1702-1705	and	abstract[71]	giv[71]	_	_
9-42	1706-1712	safety	abstract[71]|abstract	giv[71]|new	coref	12-8[96_0]
9-43	1713-1714	.	_	_	_	_

#Text=Here we focus our attention on pterostilbene ( Pt ; 3,5-dimethylresveratrol ) , an analogue of resveratrol that differs from the latter for the presence of two methyl groups .
10-1	1715-1719	Here	_	_	_	_
10-2	1720-1722	we	person	acc	ana	10-4
10-3	1723-1728	focus	_	_	_	_
10-4	1729-1732	our	person|abstract[78]	giv|new[78]	ana	24-16
10-5	1733-1742	attention	abstract[78]	new[78]	_	_
10-6	1743-1745	on	_	_	_	_
10-7	1746-1759	pterostilbene	substance	new	coref	13-1
10-8	1760-1761	(	_	_	_	_
10-9	1762-1764	Pt	abstract	new	appos	10-11
10-10	1765-1766	;	_	_	_	_
10-11	1767-1790	3,5-dimethylresveratrol	abstract	giv	appos	10-14[82_0]
10-12	1791-1792	)	_	_	_	_
10-13	1793-1794	,	_	_	_	_
10-14	1795-1797	an	abstract[82]	giv[82]	coref	14-7[0_82]
10-15	1798-1806	analogue	abstract[82]	giv[82]	_	_
10-16	1807-1809	of	abstract[82]	giv[82]	_	_
10-17	1810-1821	resveratrol	abstract[82]|substance[83]	giv[82]|new[83]	coref	11-16[93_83]
10-18	1822-1826	that	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-19	1827-1834	differs	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-20	1835-1839	from	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-21	1840-1843	the	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-22	1844-1850	latter	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-23	1851-1854	for	abstract[82]|substance[83]	giv[82]|new[83]	_	_
10-24	1855-1858	the	abstract[82]|substance[83]|abstract[84]	giv[82]|new[83]|new[84]	ana	11-1[0_84]
10-25	1859-1867	presence	abstract[82]|substance[83]|abstract[84]	giv[82]|new[83]|new[84]	_	_
10-26	1868-1870	of	abstract[82]|substance[83]|abstract[84]	giv[82]|new[83]|new[84]	_	_
10-27	1871-1874	two	abstract[82]|substance[83]|abstract[84]|person[86]	giv[82]|new[83]|new[84]|new[86]	coref	24-16[204_86]
10-28	1875-1881	methyl	abstract[82]|substance[83]|abstract[84]|organization|person[86]	giv[82]|new[83]|new[84]|new|new[86]	_	_
10-29	1882-1888	groups	abstract[82]|substance[83]|abstract[84]|person[86]	giv[82]|new[83]|new[84]|new[86]	_	_
10-30	1889-1890	.	_	_	_	_

#Text=Its increased lipophilicity accounts for its ability to reach higher tissue levels in comparison to resveratrol ’s .
11-1	1891-1894	Its	abstract|substance[88]	giv|new[88]	ana	11-6
11-2	1895-1904	increased	substance[88]	new[88]	_	_
11-3	1905-1918	lipophilicity	substance[88]	new[88]	_	_
11-4	1919-1927	accounts	_	_	_	_
11-5	1928-1931	for	_	_	_	_
11-6	1932-1935	its	abstract|abstract[90]	giv|new[90]	coref	22-9[189_90]
11-7	1936-1943	ability	abstract[90]	new[90]	_	_
11-8	1944-1946	to	abstract[90]	new[90]	_	_
11-9	1947-1952	reach	abstract[90]	new[90]	_	_
11-10	1953-1959	higher	abstract[90]|abstract[92]	new[90]|new[92]	coref	27-25[229_92]
11-11	1960-1966	tissue	abstract[90]|object|abstract[92]	new[90]|new|new[92]	coref	14-41[120_0]
11-12	1967-1973	levels	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-13	1974-1976	in	abstract[90]	new[90]	_	_
11-14	1977-1987	comparison	abstract[90]	new[90]	_	_
11-15	1988-1990	to	abstract[90]	new[90]	_	_
11-16	1991-2002	resveratrol	abstract[90]|substance[93]	new[90]|giv[93]	_	_
11-17	2003-2005	’s	abstract[90]|substance[93]	new[90]|giv[93]	_	_
11-18	2006-2007	.	_	_	_	_

#Text=Moreover , there is no concern about its safety .
12-1	2008-2016	Moreover	_	_	_	_
12-2	2017-2018	,	_	_	_	_
12-3	2019-2024	there	_	_	_	_
12-4	2025-2027	is	_	_	_	_
12-5	2028-2030	no	abstract[94]	new[94]	ana	12-8[0_94]
12-6	2031-2038	concern	abstract[94]	new[94]	_	_
12-7	2039-2044	about	abstract[94]	new[94]	_	_
12-8	2045-2048	its	abstract[94]|abstract|abstract[96]	new[94]|giv|giv[96]	_	_
12-9	2049-2055	safety	abstract[94]|abstract[96]	new[94]|giv[96]	_	_
12-10	2056-2057	.	_	_	_	_

#Text=Pterostilbene has already been shown to have positive effects in combating obesity and related disorders .
13-1	2058-2071	Pterostilbene	substance	giv	_	_
13-2	2072-2075	has	_	_	_	_
13-3	2076-2083	already	_	_	_	_
13-4	2084-2088	been	_	_	_	_
13-5	2089-2094	shown	_	_	_	_
13-6	2095-2097	to	_	_	_	_
13-7	2098-2102	have	_	_	_	_
13-8	2103-2111	positive	abstract[98]	giv[98]	coref	15-5[127_98]
13-9	2112-2119	effects	abstract[98]	giv[98]	_	_
13-10	2120-2122	in	abstract[98]	giv[98]	_	_
13-11	2123-2132	combating	abstract[98]	giv[98]	_	_
13-12	2133-2140	obesity	abstract[98]|abstract|abstract[100]	giv[98]|giv|giv[100]	coref|coref	14-5|16-7[133_100]
13-13	2141-2144	and	abstract[98]|abstract[100]	giv[98]|giv[100]	_	_
13-14	2145-2152	related	abstract[98]|abstract[100]|abstract[101]	giv[98]|giv[100]|giv[101]	_	_
13-15	2153-2162	disorders	abstract[98]|abstract[100]|abstract[101]	giv[98]|giv[100]|giv[101]	_	_
13-16	2163-2164	.	_	_	_	_

#Text=In rat models of obesity , Pt reduces fat accumulation and ameliorates liver steatosis modulating lipolysis , lipogenesis , fatty acid oxidation , improves glycemic control by modulating glycolysis , gluconeogenesis , and glucose uptake , increases thermogenic markers in brown adipose tissue , and induces changes in the gut microbiota towards a healthier composition .
14-1	2165-2167	In	_	_	_	_
14-2	2168-2171	rat	animal|abstract[103]	new|new[103]	_	_
14-3	2172-2178	models	abstract[103]	new[103]	_	_
14-4	2179-2181	of	abstract[103]	new[103]	_	_
14-5	2182-2189	obesity	abstract[103]|abstract	new[103]|giv	coref	16-7
14-6	2190-2191	,	_	_	_	_
14-7	2192-2194	Pt	abstract	giv	coref	15-3
14-8	2195-2202	reduces	_	_	_	_
14-9	2203-2206	fat	event[106]	new[106]	_	_
14-10	2207-2219	accumulation	event[106]	new[106]	_	_
14-11	2220-2223	and	_	_	_	_
14-12	2224-2235	ameliorates	_	_	_	_
14-13	2236-2241	liver	object|abstract[108]	new|new[108]	_	_
14-14	2242-2251	steatosis	abstract[108]	new[108]	_	_
14-15	2252-2262	modulating	_	_	_	_
14-16	2263-2272	lipolysis	substance	new	_	_
14-17	2273-2274	,	_	_	_	_
14-18	2275-2286	lipogenesis	substance	new	_	_
14-19	2287-2288	,	_	_	_	_
14-20	2289-2294	fatty	substance[111]|abstract[112]	new[111]|new[112]	ana	15-5[0_111]
14-21	2295-2299	acid	substance[111]|abstract[112]	new[111]|new[112]	_	_
14-22	2300-2309	oxidation	abstract[112]	new[112]	_	_
14-23	2310-2311	,	_	_	_	_
14-24	2312-2320	improves	_	_	_	_
14-25	2321-2329	glycemic	abstract[113]	new[113]	_	_
14-26	2330-2337	control	abstract[113]	new[113]	_	_
14-27	2338-2340	by	_	_	_	_
14-28	2341-2351	modulating	_	_	_	_
14-29	2352-2362	glycolysis	substance	new	_	_
14-30	2363-2364	,	_	_	_	_
14-31	2365-2380	gluconeogenesis	substance	new	_	_
14-32	2381-2382	,	_	_	_	_
14-33	2383-2386	and	_	_	_	_
14-34	2387-2394	glucose	substance|abstract[117]	new|new[117]	coref	26-3
14-35	2395-2401	uptake	abstract[117]	new[117]	_	_
14-36	2402-2403	,	_	_	_	_
14-37	2404-2413	increases	_	_	_	_
14-38	2414-2425	thermogenic	abstract[118]	new[118]	_	_
14-39	2426-2433	markers	abstract[118]	new[118]	_	_
14-40	2434-2436	in	abstract[118]	new[118]	_	_
14-41	2437-2442	brown	abstract[118]|animal[119]|object[120]	new[118]|new[119]|giv[120]	coref|coref	15-9[0_119]|15-9[129_120]
14-42	2443-2450	adipose	abstract[118]|animal[119]|object[120]	new[118]|new[119]|giv[120]	_	_
14-43	2451-2457	tissue	abstract[118]|object[120]	new[118]|giv[120]	_	_
14-44	2458-2459	,	_	_	_	_
14-45	2460-2463	and	_	_	_	_
14-46	2464-2471	induces	_	_	_	_
14-47	2472-2479	changes	abstract[121]	giv[121]	_	_
14-48	2480-2482	in	abstract[121]	giv[121]	_	_
14-49	2483-2486	the	abstract[121]|substance[123]	giv[121]|new[123]	_	_
14-50	2487-2490	gut	abstract[121]|abstract|substance[123]	giv[121]|new|new[123]	_	_
14-51	2491-2501	microbiota	abstract[121]|substance[123]	giv[121]|new[123]	_	_
14-52	2502-2509	towards	_	_	_	_
14-53	2510-2511	a	abstract[124]	new[124]	_	_
14-54	2512-2521	healthier	abstract[124]	new[124]	_	_
14-55	2522-2533	composition	abstract[124]	new[124]	_	_
14-56	2534-2535	.	_	_	_	_

#Text=Furthermore , Pt exerts its beneficial effects combating adipose tissue inflammation .
15-1	2536-2547	Furthermore	_	_	_	_
15-2	2548-2549	,	_	_	_	_
15-3	2550-2552	Pt	abstract	giv	coref	22-12[190_0]
15-4	2553-2559	exerts	_	_	_	_
15-5	2560-2563	its	substance|abstract[127]	giv|giv[127]	coref	23-1[194_127]
15-6	2564-2574	beneficial	abstract[127]	giv[127]	_	_
15-7	2575-2582	effects	abstract[127]	giv[127]	_	_
15-8	2583-2592	combating	abstract[127]	giv[127]	_	_
15-9	2593-2600	adipose	abstract[127]|animal|object[129]|abstract[130]	giv[127]|giv|giv[129]|new[130]	coref	17-12[141_129]
15-10	2601-2607	tissue	abstract[127]|object[129]|abstract[130]	giv[127]|giv[129]|new[130]	_	_
15-11	2608-2620	inflammation	abstract[127]|abstract[130]	giv[127]|new[130]	_	_
15-12	2621-2622	.	_	_	_	_

#Text=An interesting therapeutic target for treating obesity and metabolic syndrome is represented by beige ( or brite , i.e. , brown-in-white ) adipocytes .
16-1	2623-2625	An	abstract[131]	new[131]	_	_
16-2	2626-2637	interesting	abstract[131]	new[131]	_	_
16-3	2638-2649	therapeutic	abstract[131]	new[131]	_	_
16-4	2650-2656	target	abstract[131]	new[131]	_	_
16-5	2657-2660	for	abstract[131]	new[131]	_	_
16-6	2661-2669	treating	abstract[131]	new[131]	_	_
16-7	2670-2677	obesity	abstract[131]|abstract|abstract[133]	new[131]|giv|giv[133]	coref	20-50
16-8	2678-2681	and	abstract[131]|abstract[133]	new[131]|giv[133]	_	_
16-9	2682-2691	metabolic	abstract[131]|abstract[133]|person|abstract[135]	new[131]|giv[133]|new|new[135]	_	_
16-10	2692-2700	syndrome	abstract[131]|abstract[133]|abstract[135]	new[131]|giv[133]|new[135]	_	_
16-11	2701-2703	is	_	_	_	_
16-12	2704-2715	represented	_	_	_	_
16-13	2716-2718	by	_	_	_	_
16-14	2719-2724	beige	abstract[136]	new[136]	coref	17-8[139_136]
16-15	2725-2726	(	abstract[136]	new[136]	_	_
16-16	2727-2729	or	abstract[136]	new[136]	_	_
16-17	2730-2735	brite	abstract[136]	new[136]	_	_
16-18	2736-2737	,	abstract[136]	new[136]	_	_
16-19	2738-2742	i.e.	abstract[136]	new[136]	_	_
16-20	2743-2744	,	abstract[136]	new[136]	_	_
16-21	2745-2759	brown-in-white	abstract[136]	new[136]	_	_
16-22	2760-2761	)	abstract[136]	new[136]	_	_
16-23	2762-2772	adipocytes	abstract[136]	new[136]	_	_
16-24	2773-2774	.	_	_	_	_

#Text=These cells are an inducible form of thermogenic adipocytes residing in subcutaneous white adipose tissue ( WAT ) and are also found in human adults .
17-1	2775-2780	These	abstract[137]	new[137]	coref	17-4[138_137]
17-2	2781-2786	cells	abstract[137]	new[137]	_	_
17-3	2787-2790	are	_	_	_	_
17-4	2791-2793	an	abstract[138]	giv[138]	coref	18-15[151_138]
17-5	2794-2803	inducible	abstract[138]	giv[138]	_	_
17-6	2804-2808	form	abstract[138]	giv[138]	_	_
17-7	2809-2811	of	abstract[138]	giv[138]	_	_
17-8	2812-2823	thermogenic	abstract[138]|abstract[139]	giv[138]|giv[139]	coref	18-1[145_139]
17-9	2824-2834	adipocytes	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-10	2835-2843	residing	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-11	2844-2846	in	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-12	2847-2859	subcutaneous	abstract[138]|abstract[139]|object[141]	giv[138]|giv[139]|giv[141]	_	_
17-13	2860-2865	white	abstract[138]|abstract[139]|abstract[140]|object[141]	giv[138]|giv[139]|new[140]|giv[141]	_	_
17-14	2866-2873	adipose	abstract[138]|abstract[139]|abstract[140]|object[141]	giv[138]|giv[139]|new[140]|giv[141]	_	_
17-15	2874-2880	tissue	abstract[138]|abstract[139]|object[141]	giv[138]|giv[139]|giv[141]	_	_
17-16	2881-2882	(	_	_	_	_
17-17	2883-2886	WAT	abstract	new	coref	20-8
17-18	2887-2888	)	_	_	_	_
17-19	2889-2892	and	_	_	_	_
17-20	2893-2896	are	_	_	_	_
17-21	2897-2901	also	_	_	_	_
17-22	2902-2907	found	_	_	_	_
17-23	2908-2910	in	_	_	_	_
17-24	2911-2916	human	animal[143]	new[143]	_	_
17-25	2917-2923	adults	animal[143]	new[143]	_	_
17-26	2924-2925	.	_	_	_	_

#Text=Beige adipocytes can derive from white adipocyte trans differentiation and from the differentiation of adipogenic progenitor cells .
18-1	2926-2931	Beige	abstract|abstract[145]	new|giv[145]	coref|coref	19-20[157_145]|20-3
18-2	2932-2942	adipocytes	abstract[145]	giv[145]	_	_
18-3	2943-2946	can	_	_	_	_
18-4	2947-2953	derive	_	_	_	_
18-5	2954-2958	from	_	_	_	_
18-6	2959-2964	white	event[148]	new[148]	coref	18-12[149_148]
18-7	2965-2974	adipocyte	animal|event[148]	new|new[148]	_	_
18-8	2975-2980	trans	person|event[148]	new|new[148]	_	_
18-9	2981-2996	differentiation	event[148]	new[148]	_	_
18-10	2997-3000	and	_	_	_	_
18-11	3001-3005	from	_	_	_	_
18-12	3006-3009	the	event[149]	giv[149]	_	_
18-13	3010-3025	differentiation	event[149]	giv[149]	_	_
18-14	3026-3028	of	event[149]	giv[149]	_	_
18-15	3029-3039	adipogenic	event[149]|abstract[151]	giv[149]|giv[151]	ana	19-1[0_151]
18-16	3040-3050	progenitor	event[149]|animal|abstract[151]	giv[149]|new|giv[151]	_	_
18-17	3051-3056	cells	event[149]|abstract[151]	giv[149]|giv[151]	_	_
18-18	3057-3058	.	_	_	_	_

#Text=They express a set of beige-specific genes , such as Cited1 and Tbx1 , but also have similarities with brown adipocytes , including abundant mitochondria , multilocular lipid droplets and expression of brown-specific genes such as uncoupling protein 1 ( UCP1 ) and Cidea ; similar to brown adipocytes , they are able to dissipate energy as heat .
19-1	3059-3063	They	abstract	giv	ana	19-51
19-2	3064-3071	express	_	_	_	_
19-3	3072-3073	a	abstract[153]	new[153]	coref	19-33[162_153]
19-4	3074-3077	set	abstract[153]	new[153]	_	_
19-5	3078-3080	of	abstract[153]	new[153]	_	_
19-6	3081-3095	beige-specific	abstract[153]	new[153]	_	_
19-7	3096-3101	genes	abstract[153]	new[153]	_	_
19-8	3102-3103	,	abstract[153]	new[153]	_	_
19-9	3104-3108	such	abstract[153]	new[153]	_	_
19-10	3109-3111	as	abstract[153]	new[153]	_	_
19-11	3112-3118	Cited1	abstract[153]|abstract	new[153]|new	_	_
19-12	3119-3122	and	abstract[153]	new[153]	_	_
19-13	3123-3127	Tbx1	abstract[153]|abstract	new[153]|new	_	_
19-14	3128-3129	,	_	_	_	_
19-15	3130-3133	but	_	_	_	_
19-16	3134-3138	also	_	_	_	_
19-17	3139-3143	have	_	_	_	_
19-18	3144-3156	similarities	abstract[156]	new[156]	_	_
19-19	3157-3161	with	abstract[156]	new[156]	_	_
19-20	3162-3167	brown	abstract[156]|abstract[157]	new[156]|giv[157]	coref	19-48[166_157]
19-21	3168-3178	adipocytes	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-22	3179-3180	,	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-23	3181-3190	including	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-24	3191-3199	abundant	abstract[156]|abstract[157]|animal[158]	new[156]|giv[157]|new[158]	_	_
19-25	3200-3212	mitochondria	abstract[156]|abstract[157]|animal[158]	new[156]|giv[157]|new[158]	_	_
19-26	3213-3214	,	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-27	3215-3227	multilocular	abstract[156]|abstract[157]|substance[160]	new[156]|giv[157]|new[160]	_	_
19-28	3228-3233	lipid	abstract[156]|abstract[157]|person|substance[160]	new[156]|giv[157]|new|new[160]	_	_
19-29	3234-3242	droplets	abstract[156]|abstract[157]|substance[160]	new[156]|giv[157]|new[160]	_	_
19-30	3243-3246	and	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-31	3247-3257	expression	abstract[156]|abstract[157]|abstract[161]	new[156]|giv[157]|new[161]	_	_
19-32	3258-3260	of	abstract[156]|abstract[157]|abstract[161]	new[156]|giv[157]|new[161]	_	_
19-33	3261-3275	brown-specific	abstract[156]|abstract[157]|abstract[161]|abstract[162]	new[156]|giv[157]|new[161]|giv[162]	coref	27-19[226_162]
19-34	3276-3281	genes	abstract[156]|abstract[157]|abstract[161]|abstract[162]	new[156]|giv[157]|new[161]|giv[162]	_	_
19-35	3282-3286	such	abstract[156]|abstract[157]|abstract[161]|abstract[162]	new[156]|giv[157]|new[161]|giv[162]	_	_
19-36	3287-3289	as	abstract[156]|abstract[157]|abstract[161]|abstract[162]	new[156]|giv[157]|new[161]|giv[162]	_	_
19-37	3290-3300	uncoupling	abstract[156]|abstract[157]|abstract[161]|abstract[162]	new[156]|giv[157]|new[161]|giv[162]	_	_
19-38	3301-3308	protein	abstract[156]|abstract[157]|abstract[161]|abstract[162]|substance[163]	new[156]|giv[157]|new[161]|giv[162]|new[163]	coref	27-26[0_163]
19-39	3309-3310	1	abstract[156]|abstract[157]|abstract[161]|abstract[162]|substance[163]	new[156]|giv[157]|new[161]|giv[162]|new[163]	_	_
19-40	3311-3312	(	_	_	_	_
19-41	3313-3317	UCP1	abstract	new	coref	27-25
19-42	3318-3319	)	_	_	_	_
19-43	3320-3323	and	_	_	_	_
19-44	3324-3329	Cidea	substance	new	_	_
19-45	3330-3331	;	_	_	_	_
19-46	3332-3339	similar	_	_	_	_
19-47	3340-3342	to	_	_	_	_
19-48	3343-3348	brown	abstract[166]	giv[166]	coref	20-3[172_166]
19-49	3349-3359	adipocytes	abstract[166]	giv[166]	_	_
19-50	3360-3361	,	_	_	_	_
19-51	3362-3366	they	abstract	giv	_	_
19-52	3367-3370	are	_	_	_	_
19-53	3371-3375	able	_	_	_	_
19-54	3376-3378	to	_	_	_	_
19-55	3379-3388	dissipate	_	_	_	_
19-56	3389-3395	energy	abstract	new	_	_
19-57	3396-3398	as	_	_	_	_
19-58	3399-3403	heat	abstract	new	_	_
19-59	3404-3405	.	_	_	_	_

#Text=Induction of beige adipocytes ( i.e. , WAT browning ) can be induced by environmental or physiological stimuli ( such as cold exposure , physical activity , or thyroid hormones ) , but also pharmacologically ( for example , with PPAR agonists ) , and could prevent or combat obesity by increasing energy consumption through non-shivering thermogenesis .
20-1	3406-3415	Induction	abstract[170]	new[170]	_	_
20-2	3416-3418	of	abstract[170]	new[170]	_	_
20-3	3419-3424	beige	abstract[170]|abstract|abstract[172]	new[170]|giv|giv[172]	coref	23-7[196_172]
20-4	3425-3435	adipocytes	abstract[170]|abstract[172]	new[170]|giv[172]	_	_
20-5	3436-3437	(	_	_	_	_
20-6	3438-3442	i.e.	event[174]	new[174]	coref	21-8[186_174]
20-7	3443-3444	,	event[174]	new[174]	_	_
20-8	3445-3448	WAT	abstract|event[174]	giv|new[174]	coref	22-17
20-9	3449-3457	browning	event[174]	new[174]	_	_
20-10	3458-3459	)	_	_	_	_
20-11	3460-3463	can	_	_	_	_
20-12	3464-3466	be	_	_	_	_
20-13	3467-3474	induced	_	_	_	_
20-14	3475-3477	by	_	_	_	_
20-15	3478-3491	environmental	abstract[175]	new[175]	_	_
20-16	3492-3494	or	abstract[175]	new[175]	_	_
20-17	3495-3508	physiological	abstract[175]	new[175]	_	_
20-18	3509-3516	stimuli	abstract[175]	new[175]	_	_
20-19	3517-3518	(	abstract[175]	new[175]	_	_
20-20	3519-3523	such	abstract[175]	new[175]	_	_
20-21	3524-3526	as	abstract[175]	new[175]	_	_
20-22	3527-3531	cold	abstract[175]|event[176]	new[175]|new[176]	_	_
20-23	3532-3540	exposure	abstract[175]|event[176]	new[175]|new[176]	_	_
20-24	3541-3542	,	abstract[175]	new[175]	_	_
20-25	3543-3551	physical	abstract[175]|abstract[177]	new[175]|giv[177]	_	_
20-26	3552-3560	activity	abstract[175]|abstract[177]	new[175]|giv[177]	_	_
20-27	3561-3562	,	abstract[175]	new[175]	_	_
20-28	3563-3565	or	abstract[175]	new[175]	_	_
20-29	3566-3573	thyroid	abstract[175]|object|substance[179]	new[175]|new|new[179]	_	_
20-30	3574-3582	hormones	abstract[175]|substance[179]	new[175]|new[179]	_	_
20-31	3583-3584	)	abstract[175]	new[175]	_	_
20-32	3585-3586	,	_	_	_	_
20-33	3587-3590	but	_	_	_	_
20-34	3591-3595	also	_	_	_	_
20-35	3596-3613	pharmacologically	_	_	_	_
20-36	3614-3615	(	_	_	_	_
20-37	3616-3619	for	_	_	_	_
20-38	3620-3627	example	abstract[181]	new[181]	_	_
20-39	3628-3629	,	abstract[181]	new[181]	_	_
20-40	3630-3634	with	abstract[181]	new[181]	_	_
20-41	3635-3639	PPAR	substance|abstract[181]	new|new[181]	_	_
20-42	3640-3648	agonists	abstract[181]	new[181]	_	_
20-43	3649-3650	)	_	_	_	_
20-44	3651-3652	,	_	_	_	_
20-45	3653-3656	and	_	_	_	_
20-46	3657-3662	could	_	_	_	_
20-47	3663-3670	prevent	_	_	_	_
20-48	3671-3673	or	_	_	_	_
20-49	3674-3680	combat	_	_	_	_
20-50	3681-3688	obesity	abstract	giv	coref	23-18[199_0]
20-51	3689-3691	by	_	_	_	_
20-52	3692-3702	increasing	_	_	_	_
20-53	3703-3709	energy	abstract[183]	new[183]	_	_
20-54	3710-3721	consumption	abstract[183]	new[183]	_	_
20-55	3722-3729	through	_	_	_	_
20-56	3730-3743	non-shivering	abstract[184]	new[184]	_	_
20-57	3744-3757	thermogenesis	abstract[184]	new[184]	_	_
20-58	3758-3759	.	_	_	_	_

#Text=Various phytochemicals have been reported to promote fat browning .
21-1	3760-3767	Various	substance[185]	new[185]	_	_
21-2	3768-3782	phytochemicals	substance[185]	new[185]	_	_
21-3	3783-3787	have	_	_	_	_
21-4	3788-3792	been	_	_	_	_
21-5	3793-3801	reported	_	_	_	_
21-6	3802-3804	to	_	_	_	_
21-7	3805-3812	promote	_	_	_	_
21-8	3813-3816	fat	event[186]	giv[186]	coref	27-8[222_186]
21-9	3817-3825	browning	event[186]	giv[186]	_	_
21-10	3826-3827	.	_	_	_	_

#Text=The aim of this study was to investigate the ability of Pt to do it in WAT .
22-1	3828-3831	The	abstract[187]	new[187]	_	_
22-2	3832-3835	aim	abstract[187]	new[187]	_	_
22-3	3836-3838	of	abstract[187]	new[187]	_	_
22-4	3839-3843	this	abstract[187]|abstract[188]	new[187]|new[188]	_	_
22-5	3844-3849	study	abstract[187]|abstract[188]	new[187]|new[188]	_	_
22-6	3850-3853	was	_	_	_	_
22-7	3854-3856	to	_	_	_	_
22-8	3857-3868	investigate	_	_	_	_
22-9	3869-3872	the	abstract[189]	giv[189]	_	_
22-10	3873-3880	ability	abstract[189]	giv[189]	_	_
22-11	3881-3883	of	abstract[189]	giv[189]	_	_
22-12	3884-3886	Pt	abstract[189]|abstract[190]	giv[189]|giv[190]	ana	22-15[0_190]
22-13	3887-3889	to	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
22-14	3890-3892	do	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
22-15	3893-3895	it	abstract[189]|abstract[190]|abstract	giv[189]|giv[190]|giv	coref	24-34
22-16	3896-3898	in	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
22-17	3899-3902	WAT	abstract[189]|abstract[190]|abstract	giv[189]|giv[190]|giv	ana	23-1
22-18	3903-3904	.	_	_	_	_

#Text=Its effects were first assayed on cultured 3T3-L1 adipocytes , and then in a mouse model of diet-induced obesity .
23-1	3905-3908	Its	abstract|abstract[194]	giv|giv[194]	coref	27-8
23-2	3909-3916	effects	abstract[194]	giv[194]	_	_
23-3	3917-3921	were	_	_	_	_
23-4	3922-3927	first	_	_	_	_
23-5	3928-3935	assayed	_	_	_	_
23-6	3936-3938	on	_	_	_	_
23-7	3939-3947	cultured	abstract[196]	giv[196]	_	_
23-8	3948-3954	3T3-L1	abstract|abstract[196]	new|giv[196]	_	_
23-9	3955-3965	adipocytes	abstract[196]	giv[196]	_	_
23-10	3966-3967	,	_	_	_	_
23-11	3968-3971	and	_	_	_	_
23-12	3972-3976	then	_	_	_	_
23-13	3977-3979	in	_	_	_	_
23-14	3980-3981	a	abstract[198]	new[198]	_	_
23-15	3982-3987	mouse	animal|abstract[198]	new|new[198]	_	_
23-16	3988-3993	model	abstract[198]	new[198]	_	_
23-17	3994-3996	of	abstract[198]	new[198]	_	_
23-18	3997-4009	diet-induced	abstract[198]|abstract[199]	new[198]|giv[199]	_	_
23-19	4010-4017	obesity	abstract[198]|abstract[199]	new[198]|giv[199]	_	_
23-20	4018-4019	.	_	_	_	_

#Text=To take into account possible gender-specific differences , both females and males were included in our experimental groups ; a 30 week-long treatment was performed , to highlight long-term effects of a chronic Pt supplementation .
24-1	4020-4022	To	_	_	_	_
24-2	4023-4027	take	_	_	_	_
24-3	4028-4032	into	_	_	_	_
24-4	4033-4040	account	_	_	_	_
24-5	4041-4049	possible	abstract[200]	new[200]	_	_
24-6	4050-4065	gender-specific	abstract[200]	new[200]	_	_
24-7	4066-4077	differences	abstract[200]	new[200]	_	_
24-8	4078-4079	,	_	_	_	_
24-9	4080-4084	both	person[201]	new[201]	_	_
24-10	4085-4092	females	person[201]	new[201]	_	_
24-11	4093-4096	and	_	_	_	_
24-12	4097-4102	males	person	new	_	_
24-13	4103-4107	were	_	_	_	_
24-14	4108-4116	included	_	_	_	_
24-15	4117-4119	in	_	_	_	_
24-16	4120-4123	our	person|person[204]	giv|giv[204]	ana	25-1
24-17	4124-4136	experimental	person[204]	giv[204]	_	_
24-18	4137-4143	groups	person[204]	giv[204]	_	_
24-19	4144-4145	;	_	_	_	_
24-20	4146-4147	a	event[206]	giv[206]	_	_
24-21	4148-4150	30	time[205]|event[206]	new[205]|giv[206]	_	_
24-22	4151-4160	week-long	time[205]|event[206]	new[205]|giv[206]	_	_
24-23	4161-4170	treatment	event[206]	giv[206]	_	_
24-24	4171-4174	was	_	_	_	_
24-25	4175-4184	performed	_	_	_	_
24-26	4185-4186	,	_	_	_	_
24-27	4187-4189	to	_	_	_	_
24-28	4190-4199	highlight	_	_	_	_
24-29	4200-4209	long-term	abstract[207]	new[207]	_	_
24-30	4210-4217	effects	abstract[207]	new[207]	_	_
24-31	4218-4220	of	abstract[207]	new[207]	_	_
24-32	4221-4222	a	abstract[207]|substance[209]	new[207]|new[209]	_	_
24-33	4223-4230	chronic	abstract[207]|substance[209]	new[207]|new[209]	_	_
24-34	4231-4233	Pt	abstract[207]|abstract|substance[209]	new[207]|giv|new[209]	coref	25-4
24-35	4234-4249	supplementation	abstract[207]|substance[209]	new[207]|new[209]	_	_
24-36	4250-4251	.	_	_	_	_

#Text=We found that Pt diminished body weight gain induced by a high-fat diet regimen ;
25-1	4252-4254	We	person	giv	_	_
25-2	4255-4260	found	_	_	_	_
25-3	4261-4265	that	_	_	_	_
25-4	4266-4268	Pt	abstract	giv	_	_
25-5	4269-4279	diminished	_	_	_	_
25-6	4280-4284	body	object|abstract[213]|abstract[214]	new|new[213]|new[214]	_	_
25-7	4285-4291	weight	abstract[213]|abstract[214]	new[213]|new[214]	_	_
25-8	4292-4296	gain	abstract[214]	new[214]	_	_
25-9	4297-4304	induced	abstract[214]	new[214]	_	_
25-10	4305-4307	by	abstract[214]	new[214]	_	_
25-11	4308-4309	a	abstract[214]|abstract[216]	new[214]|new[216]	_	_
25-12	4310-4318	high-fat	abstract[214]|abstract[216]	new[214]|new[216]	_	_
25-13	4319-4323	diet	abstract[214]|abstract|abstract[216]	new[214]|new|new[216]	_	_
25-14	4324-4331	regimen	abstract[214]|abstract[216]	new[214]|new[216]	_	_
25-15	4332-4333	;	_	_	_	_

#Text=also , glucose homeostasis was partially preserved , at least up to week 18 .
26-1	4334-4338	also	_	_	_	_
26-2	4339-4340	,	_	_	_	_
26-3	4341-4348	glucose	substance|abstract[218]	giv|new[218]	_	_
26-4	4349-4360	homeostasis	abstract[218]	new[218]	_	_
26-5	4361-4364	was	_	_	_	_
26-6	4365-4374	partially	_	_	_	_
26-7	4375-4384	preserved	_	_	_	_
26-8	4385-4386	,	_	_	_	_
26-9	4387-4389	at	time[219]	new[219]	_	_
26-10	4390-4395	least	time[219]	new[219]	_	_
26-11	4396-4398	up	time[219]	new[219]	_	_
26-12	4399-4401	to	time[219]	new[219]	_	_
26-13	4402-4406	week	time[219]	new[219]	_	_
26-14	4407-4409	18	time[219]	new[219]	_	_
26-15	4410-4411	.	_	_	_	_

#Text=Interestingly , Pt was able to induce WAT browning , leading to an increase in the transcription of beige- and brown-related genes and of UCP1 protein levels , which , however , did not achieve significance .
27-1	4412-4425	Interestingly	_	_	_	_
27-2	4426-4427	,	_	_	_	_
27-3	4428-4430	Pt	person	new	_	_
27-4	4431-4434	was	_	_	_	_
27-5	4435-4439	able	_	_	_	_
27-6	4440-4442	to	_	_	_	_
27-7	4443-4449	induce	_	_	_	_
27-8	4450-4453	WAT	abstract|event[222]	giv|giv[222]	_	_
27-9	4454-4462	browning	event[222]	giv[222]	_	_
27-10	4463-4464	,	_	_	_	_
27-11	4465-4472	leading	_	_	_	_
27-12	4473-4475	to	_	_	_	_
27-13	4476-4478	an	event[223]	new[223]	_	_
27-14	4479-4487	increase	event[223]	new[223]	_	_
27-15	4488-4490	in	event[223]	new[223]	_	_
27-16	4491-4494	the	event[223]|abstract[224]	new[223]|new[224]	_	_
27-17	4495-4508	transcription	event[223]|abstract[224]	new[223]|new[224]	_	_
27-18	4509-4511	of	event[223]|abstract[224]	new[223]|new[224]	_	_
27-19	4512-4518	beige-	event[223]|abstract[224]|object|abstract[226]	new[223]|new[224]|new|giv[226]	_	_
27-20	4519-4522	and	event[223]|abstract[224]|abstract[226]	new[223]|new[224]|giv[226]	_	_
27-21	4523-4536	brown-related	event[223]|abstract[224]|abstract[226]	new[223]|new[224]|giv[226]	_	_
27-22	4537-4542	genes	event[223]|abstract[224]|abstract[226]	new[223]|new[224]|giv[226]	_	_
27-23	4543-4546	and	event[223]	new[223]	_	_
27-24	4547-4549	of	event[223]	new[223]	_	_
27-25	4550-4554	UCP1	event[223]|abstract|abstract[229]	new[223]|giv|giv[229]	_	_
27-26	4555-4562	protein	event[223]|substance|abstract[229]	new[223]|giv|giv[229]	_	_
27-27	4563-4569	levels	event[223]|abstract[229]	new[223]|giv[229]	_	_
27-28	4570-4571	,	event[223]	new[223]	_	_
27-29	4572-4577	which	event[223]	new[223]	_	_
27-30	4578-4579	,	event[223]	new[223]	_	_
27-31	4580-4587	however	event[223]	new[223]	_	_
27-32	4588-4589	,	event[223]	new[223]	_	_
27-33	4590-4593	did	event[223]	new[223]	_	_
27-34	4594-4597	not	event[223]	new[223]	_	_
27-35	4598-4605	achieve	event[223]	new[223]	_	_
27-36	4606-4618	significance	event[223]|abstract	new[223]|new	_	_
27-37	4619-4620	.	_	_	_	_
